Cost Challenges in Developing New Oncology Drugs
December 4th 2013
The increased cost of new branded oncology drugs continues to receive much negative press. Recent editorials have criticized the high cost of new cancer therapies, and their less than stellar improvements in efficacy, over already existing, lower-cost treatment options. Such critics have argued that little or no correlation between drug efficacies and pricing exists.